trial

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCTId NCT00487942
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60 (actual)
Sponsored by Cephalon
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-07
Primary completion
2007-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
armodafinil

Sponsors

CephalonLead Sponsor

Sites

12 total
Garden Grove, United StatesNational City, United StatesParamount, United StatesPico Rivera, United StatesSan Diego, United StatesNew Haven, United StatesAtlanta, United StatesChicago, United StatesSt Louis, United StatesDurham, United StatesDayton, United StatesIrving, United States

Linked catalysts

1
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults — primary completion2007-12

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
armodafinil
drug
lead_sponsor
Cephalon
company
indication
Schizophrenia
indication
Schizophrenia
indication